GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » 10-Year ROIIC %

Egyptian International Pharmaceutical Investments (CAI:PHAR) 10-Year ROIIC % : 0.00% (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Egyptian International Pharmaceutical Investments's 10-Year ROIIC % for the quarter that ended in Dec. 2023 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Egyptian International Pharmaceutical Investments's 10-Year ROIIC % or its related term are showing as below:

CAI:PHAR's 10-Year ROIIC % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 3.12
* Ranked among companies with meaningful 10-Year ROIIC % only.

Egyptian International Pharmaceutical Investments 10-Year ROIIC % Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments 10-Year ROIIC % Chart

Egyptian International Pharmaceutical Investments Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.40 - -

Egyptian International Pharmaceutical Investments Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Egyptian International Pharmaceutical Investments's 10-Year ROIIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Egyptian International Pharmaceutical Investments's 10-Year ROIIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Egyptian International Pharmaceutical Investments's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Egyptian International Pharmaceutical Investments's 10-Year ROIIC % falls into.



Egyptian International Pharmaceutical Investments 10-Year ROIIC % Calculation

Egyptian International Pharmaceutical Investments's 10-Year ROIIC % for the quarter that ended in Dec. 2023 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( 997.27048 (Dec. 2023) - 0 (Dec. 2013) )/( 8741.988 (Dec. 2023) - 1997.471 (Dec. 2013) )
=/6744.517
=0.00%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Egyptian International Pharmaceutical Investments  (CAI:PHAR) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Egyptian International Pharmaceutical Investments 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Traded in Other Exchanges
N/A
Address
1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.